Please login to the form below

Not currently logged in
Email:
Password:

Valeant adds member to board of directors

President of ValueAct Capital G. Mason Morfitadded to team
Valeant Mason Morfit

Valeant Pharmaceuticals has added G. Mason Morfit, president of ValueAct Capital to its board of directors, effective immediately.

Morfit also currently serves on the board of directors for Microsoft and was former director of CR Bard, Immucor, Advanced Medical Optics and Solexa prior to his role at ValueAct Capital.

Morfit had originally served on Valeant's board of directors between 2007 and 2014.

Michael Pearson, chairman and CEO of Valeant, said: “I am pleased to welcome Mason back to the Valeant board of directors.

“Although Mason has not officially been a part of the Valeant board for more than a year, I have continued to value his vision and guidance, and I believe his insights will be invaluable during this time.”

26th October 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics